Why the study?
To evaluate markers of renal dysfunction in relation to the risk of atrial fibrillation in patients following STEMI treated with primary PCI.
Observational (n=152)
Cystatin C and NT-proBNP are significant prognostic markers for the development of atrial fibrillation in patients recovering from STEMI.
Aim. To study markers of renal dysfunction in relation to the likelihood of atrial fibrillation (AF) in patients after ST-segment elevated myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). Material and methods . The study was conducted with the inclusion of 1 52 patients discharged for outpatient monitoring after STEMI. There were 4 visits: V 1 - inclusion visit, V 2 - in 12 months, V 3 - in 18 months, V 4 - in 24 months with determination of plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP), cystatin C, erythropoietin, galectin-3, von Willebrand factor (fW), left ventricular ejection fraction. Endpoint: new cases of AF, cardioembolic stroke, deaths. Results. After 24 months 35 patients (23.0%) were diagnosed with AF, 6 of them (3.9%) - developed cardioembolic stroke. The multivariate model of risk factors for AF included indicators: cystatin C (odds ratio [OR] 1.31; 95% confidence interval [95%CI] 1.03-1.67), NT-ProBNP (OR 1.11; 95%CI 1.03-1.19), galectin-3 (OR 0.71; 95%CI 0.55-0.91), fV (OR 0.71; 95%CI 0.55-0.91). Conclusion. The prognostic significance of cystatin C in relation to the risk of AF was established, which should be considered when assessing the prognosis in patients after STEMI.
No takes yet. Share an insight, caveat, or question.
Zolotovskaya et al. (2019) conducted an observational in ST-segment elevated myocardial infarction (STEMI) (n=152). Cystatin C was evaluated on new cases of atrial fibrillation (OR 1.31, 95% CI 1.03-1.67).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: